| Variable | Patient group | ||
| PD-RBD (n = 26) | PD-nonRBD (n = 29) | p | |
| Gender (male) | 61.5% | 62.1% | 0.97 |
| Age (years) | 63.5 ± 9.1 | 60.6 ± 12.6 | 0.22 |
| Age of onset (years) | 61.2 ± 10.7 | 58.2 ± 11.1 | 0.41 |
| Duration of PD (years) | 7.4 ± 8.3 | 5.6 ± 4.8 | 0.34 |
| Hoehn and Yahr stage | 2.2 ± 0.7 | 2.1 ± 0.6 | 0.42 |
| LEDD (mg) | 734.4 ± 485.6 | 546.6 ± 355.6 | 0.11 |
| DA-LEDD(mg) | 181.5 ± 147.1 | 131.1 ± 126.7 | 0.18 |
| Use of dopamine agonist | 84.6% | 75.9% | 0.42 |
| Use of Levodopa | 76.9% | 75.9% | 0.93 |